Bioqual, Inc. (BIOQ)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 58 | 66 | 63 | 59 | 49 | - | 40 | - |
| Operating profit | $m | -2 | -4 | ||||||
| Net profit | $m | 6 | 5 | 1 | 0 | -1 | - | -4 | - |
| EPS reported | $ | -1.17 | -4.66 | ||||||
| Operating cashflow per share | $ | 3.29 | 7.03 | ||||||
| Capex per share | $ | 0.27 | 0.39 | ||||||
| FCF per share | $ | 3.03 | 6.64 | ||||||
| Free cash flow | $m | 3 | -0 | ||||||
| Net debt | $m | -14 | 17 | ||||||
| Book value equity | $m | 36 | 32 | ||||||
| Book value per share | $ | 40.42 | 36.23 | ||||||
| Number of shares | m | 0.89 | 0.89 | ||||||
| DPS (TTM paid) | $ | 0.50 | 0.00 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | - | - | ||||||
| P/B LTM | x | 1.79 | 1.24 | ||||||
| P/S LTM | x | 1.33 | 1.01 | ||||||
| P/FCF LTM | x | 23.96 | -602.80 | ||||||
| EV/EBITDA LTM | x | 103.68 | -43.68 | ||||||
| EV/Sales LTM | x | 0.80 | 1.22 | ||||||
| Earnings Yield LTM | % | -2.60% | -4.19% | ||||||
| FCF Yield | % | +4.17% | -0.17% | ||||||
| Quality | |||||||||
| ROE | % | -2.90% | -3.46% | ||||||
| ROIC | % | -2.93% | -2.67% | ||||||
| Operating margin | % | -3.88% | -5.40% | ||||||
| Gross margin | % | -3.88% | -6.99% | ||||||
| FCF/Sales | % | +5.54% | +14.02% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | - | ||||||
| Sales Growth YoY | % | -16.60% | -18.25% | ||||||
| Net Income Growth YoY | % | - | - | ||||||
| FCF Growth | % | -69.12% | - | ||||||
| Operating Profit Growth | % | - | - | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | +1.11% | 0.00% | ||||||
| Dividend Growth | % | 0.00% | -100.00% | ||||||
| Payout Ratio | % | -42.67% | 0.00% | ||||||
| FCF/Debt | x | 0.16 | -0.00 | ||||||
| Net Debt/EBITDA | x | -2.58 | 16.45 | ||||||
| EBIT/Net interest | x | 0.00 | 0.00 | ||||||
| Net debt/market cap | % | +9.92% | +10.70% | ||||||
| Net debt/Equity | x | -0.38 | 0.52 | ||||||
| Gross debt/equity | x | 0.46 | 1.01 | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
Bioqual, Inc. delivers a range of preclinical research solutions, encompassing both in-vivo and in-vitro methodologies, to its diverse clientele of commercial enterprises and government agencies across the United States. Their expertise spans numerous critical health domains, including investigations into COVID-19, AIDS, influenza, RSV infection, and various flaviviruses such as Zika and Dengue. Furthermore, their work extends to malaria, hepatitis, and oncology. The firm's comprehensive laboratory capabilities further include processing biological samples, producing virus stocks, precisely quantifying infectious viral loads, and conducting assays like virus neutralization and hemagglutination inhibition. They also utilize advanced techniques such as quantitative PCR, ELISA for antigen and antibody detection, flow cytometry, lymphocyte proliferation studies, and various other cell-based analytical methods. Moreover, Bioqual furnishes specialized support for studies employing animal research models. Established in 1981, Bioqual, Inc. maintains its primary operational base in Rockville, Maryland.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
No price history available.
Not enough data to calculate KvantraRank
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
Bioqual, Inc. delivers a range of preclinical research solutions, encompassing both in-vivo and in-vitro methodologies, to its diverse clientele of commercial enterprises and government agencies across the United States. Their expertise spans numerous critical health domains, including investigations into COVID-19, AIDS, influenza, RSV infection, and various flaviviruses such as Zika and Dengue. Furthermore, their work extends to malaria, hepatitis, and oncology. The firm's comprehensive laboratory capabilities further include processing biological samples, producing virus stocks, precisely quantifying infectious viral loads, and conducting assays like virus neutralization and hemagglutination inhibition. They also utilize advanced techniques such as quantitative PCR, ELISA for antigen and antibody detection, flow cytometry, lymphocyte proliferation studies, and various other cell-based analytical methods. Moreover, Bioqual furnishes specialized support for studies employing animal research models. Established in 1981, Bioqual, Inc. maintains its primary operational base in Rockville, Maryland.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free